Saturday, February 02, 2019 11:43:13 AM
Childbearing women produce greater amounts of choline... see link contained.
Interesting link, GAB. Thanks for posting that find!
In my opinion “Is it good for AVXL?”, yes, it could help understand and explain our compound vis a vis other sigma 1 receptor agonists, such as donepezil, in its ability to TREAT Alzheimer’s Disease.
However, sadly, it does not adequately account for the glaring statistic that women suffer AD 2:1 over men, and therefore, if one is searching for the CAUSE, this doesn’t get us there.
Note the levels of choline in females and males in this article which presents contradictory evidence to the Jan 9, 2019 study findings:
https://academic.oup.com/ajcn/article/92/5/1113/4597519
Females during childbearing years produce more choline. Pregnant and breastfeeding women produce less choline and require slightly more (through supplements). Men produce less as do postmenopausal women and require even greater levels of supplementation.
> The implication being that men would suffer AD at higher rates - barring supplementation. We know this is not the case.
This is because choline is derived from estrogen. (From my cite)
But, the original cite, the Jan 9 study, notes that progesterone is a “notable” S1r binder with no extracellular stimuli affecting regulation (occupies/binds but has no effect and therefore inhibits other agonists such as choline from binding and agonizing.)
If true, as stated, this does not get us to the disparity of the prevalence - male/female, does it?
My assessment is that this is encouraging in the treatment of disease (the business Anavex is in), but has not unlocked the cause, YET.
I say “yet” because I anticipate literature linking progesterone’s role as a recurring temporary blocker/inhibitor which presents an opportunity for protein misfolding to occur repeatedly and marinate over years, as this will now be seen as a necessary dot to connect. Once that link is made, the cause will become clearer.
At which time, the FDA and BP’s and early movements by organizations championing the approval of birth control pill contraception for women will be in the position of “they knew not what they wrought”. The sigma 1 was not known of - they could not have foreseen this coming.
Be careful what you ask for, you might get it....that’s a high price to pay, imo.
Two cents,
Bio
And, as long as we are being scientific, the groundhog predicts an early spring! :)
Interesting link, GAB. Thanks for posting that find!
In my opinion “Is it good for AVXL?”, yes, it could help understand and explain our compound vis a vis other sigma 1 receptor agonists, such as donepezil, in its ability to TREAT Alzheimer’s Disease.
However, sadly, it does not adequately account for the glaring statistic that women suffer AD 2:1 over men, and therefore, if one is searching for the CAUSE, this doesn’t get us there.
Note the levels of choline in females and males in this article which presents contradictory evidence to the Jan 9, 2019 study findings:
https://academic.oup.com/ajcn/article/92/5/1113/4597519
Females during childbearing years produce more choline. Pregnant and breastfeeding women produce less choline and require slightly more (through supplements). Men produce less as do postmenopausal women and require even greater levels of supplementation.
> The implication being that men would suffer AD at higher rates - barring supplementation. We know this is not the case.
This is because choline is derived from estrogen. (From my cite)
But, the original cite, the Jan 9 study, notes that progesterone is a “notable” S1r binder with no extracellular stimuli affecting regulation (occupies/binds but has no effect and therefore inhibits other agonists such as choline from binding and agonizing.)
If true, as stated, this does not get us to the disparity of the prevalence - male/female, does it?
My assessment is that this is encouraging in the treatment of disease (the business Anavex is in), but has not unlocked the cause, YET.
I say “yet” because I anticipate literature linking progesterone’s role as a recurring temporary blocker/inhibitor which presents an opportunity for protein misfolding to occur repeatedly and marinate over years, as this will now be seen as a necessary dot to connect. Once that link is made, the cause will become clearer.
At which time, the FDA and BP’s and early movements by organizations championing the approval of birth control pill contraception for women will be in the position of “they knew not what they wrought”. The sigma 1 was not known of - they could not have foreseen this coming.
Be careful what you ask for, you might get it....that’s a high price to pay, imo.
Two cents,
Bio
And, as long as we are being scientific, the groundhog predicts an early spring! :)
Recent AVXL News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
